Rory B. Riggs - Jan 2, 2024 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
Director
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for Rory B. Riggs
Stock symbol
RPRX
Transactions as of
Jan 2, 2024
Transactions value $
-$13,222,862
Form type
4
Date filed
1/4/2024, 05:16 PM
Previous filing
Jan 3, 2024
Next filing
Feb 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale -$6.71M -235K -47.99% $28.52 255K Jan 2, 2024 Direct F1
transaction RPRX Class A Ordinary Shares Sale -$5.53M -199K -78.11% $27.79 55.8K Jan 3, 2024 Direct F2
transaction RPRX Class A Ordinary Shares Sale -$984K -35.7K -63.98% $27.55 20.1K Jan 4, 2024 Direct F3
holding RPRX Class A Ordinary Shares 85.2K Jan 2, 2024 By New Ventures III LLC
holding RPRX Class A Ordinary Shares 15K Jan 2, 2024 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.79 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.48 to $28.26 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.36 to $27.79 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.